Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
It is an open-lable, single-arm, single-center, phase II clinical trial conducted in China, and plan to recruiting 20 patients who were progressed after first line chemotherapy or chemotherapy combined with immunotherapy. The purpose of this study is to evaluate the safety and efficacy of tislelizumab combined with anlotinib as second-line in thymoma and thymic carcinoma.
Thymic Carcinoma|Thymoma
DRUG: Experimental: tislelizumab+anlotinib
Objective Response Rate (ORR), Objective Response Rate (ORR) refers to the proportion of patients whose cancer shrinks (partial response) or disappears (complete response) after treatment., Two years of observation after enrollment
Overall Survival (OS), The time from enrollment to death due to any reason., Two years of observation after enrollment|Progression free survival (PFS), The time from the beginning of randomization to the progression of tumor development or death for any reason., Two year of observation after enrollment|Duration of response (DOR), DOR was defined as the time from first documented evidence of a CR or PR until progressive disease (PD) or death., 24 months
It is an open-lable, single-arm, single-center, phase II clinical trial conducted in China, and plan to recruiting 20 patients who were progressed after first line chemotherapy or chemotherapy combined with immunotherapy. The purpose of this study is to evaluate the safety and efficacy of tislelizumab combined with anlotinib as second-line in thymoma and thymic carcinoma.